Avivagen Inc. (TSXV:VIV) (OTC Pink:CHEXF)
(“
Avivagen” or the “
Company”), a
life sciences innovation company with a series of patent protected
products that support and optimize human and animal health, is
pleased to announce that it has entered into a two-year
distribution agreement with
PACC Pets. The
agreement, for Avivagen’s companion animal health product VIVAMUNE
HEALTH CHEWS, is for the United States only and is non-exclusive,
except for the state of Florida, for which Avivagen has granted
exclusive distribution rights for an initial six-month period. In
addition, PACC Pets will be featuring Vivamune in the New Product
Showcase at Global Pet Expo, the largest pet product industry
trade show in the world, from March 21st-23rd, 2018 in Orlando,
Florida.
Kym Anthony, Avivagen’s Chairman & Interim CEO stated, “We
are very pleased and excited to be partnering with PACC Pets
regarding our Vivamune Health Chews product and to be attending the
Global Pet Expo. We view this agreement as another validation of
our OxC-beta technology and we look forward to working with and
expanding our relationship with this unique and innovative company
and showcasing Vivamune Health Chews at Global Pet Expo.”
ABOUT PACC PETSA growing and dynamic company,
PACC Pets, LLC is dedicated to distributing innovative and unique
high-quality pet products throughout the United States and Canada.
Its substantial retail network includes larger retail chains,
online suppliers and individual pet stores.
PACC Pets is also a global distributor with distribution
connections in the following countries:
- LATIN AMERICA: Mexico, Costa Rica, Panama, Guatemala, Colombia,
Chile, Peru, Argentina and Brazil
- EUROPE: Poland, Germany, Italy, Netherlands, Portugal
- MIDDLE EAST: Israel, Turkey, Egypt, United Arab Emirates,
Lebanon, Cyprus
- ASIA: Korea, China, Hong Kong, Taiwan, Japan, Singapore,
Thailand, Malaysia
ABOUT GLOBAL PET EXPOVivamune will be featured
at GLOBAL PET EXPO for the first time from March
21st -23rd in Orlando Florida. Presented by the American Pet
Products Association (APPA) and Pet Industry Distributors
Association (PIDA), Global Pet Expo is the pet industry's
largest annual trade show featuring the newest, most innovative pet
products on the market today.
The 2017 Showcase featured 1,130 exhibitors, 3,437 booths, 3,000
new product launches and more than 6,700 pet product buyers,
including a significant number of international retailers.
2018’s Expo will include the New Products Showcase
which gives exhibitors the opportunity to highlight their newest
lines while getting additional exposure for their products at
Global Pet Expo. It is also an opportunity for key international
and domestic buyers to see what's new and exciting in the industry.
The New Product Showcase receives a great deal of interest at the
Show as well as coverage in numerous trade publications. With
hundreds of entries, this is the largest new products showcase
at any pet product industry trade show in the world.
About AvivagenAvivagen Inc. is
a public corporation traded on the TSX Venture Exchange under the
symbol VIV and is headquartered in Ottawa, Canada, based in
partnership facilities of the National Research Council of Canada
and Charlottetown, Prince Edward Island. For more information,
visit www.avivagen.com.
About Vivamune™ Health Chews
(Vivamune)Vivamune is an all-in-one chew that can
dramatically simplify a pet’s supplement routine. Featuring a
newly-discovered, novel immune-supporting active ingredient:
OxC-beta™ compound, Vivamune targets joints, skin and digestive
health all in a single, tasty chew a pet will love. Vivamune is
available for sale in the United States. For more information,
visit www.vivamunehealth.com.
About OxC-beta™ Technology and OxC-beta™
LivestockAvivagen’s OxC-beta™ technology is
derived from Avivagen discoveries about carotenoids, compounds that
give certain fruits and vegetables their bright colors and is a
non-antibiotic means of maintaining optimal health and growth.
OxC-beta™ Livestock is a proprietary product shown to be effective
and economic in replacing the antibiotics commonly added to
livestock feeds. OxC-beta™ Livestock is currently registered and
available for sale in the Philippines, Taiwan and Thailand.
Avivagen’s OxC-beta™ Livestock product is safe,
effective and could fulfill the global mandate to remove all
in-feed antibiotics as growth promoters. Numerous international
livestock trials with poultry and swine using OxC-beta™ Livestock
have proven that the product performs as well as, and, sometimes,
in some aspects, better than in-feed antibiotics.
Forward Looking StatementsThis
news release includes certain forward-looking statements that are
based upon the current expectations of management. Forward-looking
statements involve risks and uncertainties associated with the
business of Avivagen Inc. and the environment in which the business
operates. Any statements contained herein that are not statements
of historical facts may be deemed to be forward-looking, including
those identified by the expressions “aim”, “anticipate”, “appear”,
“believe”, “consider”, “could”, “estimate”, “expect”, “if”,
“intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”,
“potentially”, “pursue”, “seem”, “should”, “whether”, “will”,
“would” and similar expressions. Statements about the future of the
distribution relationship between Avivagen Inc. and PACC Pets and
about the Global Pet Expo set out in this news release are
forward-looking statements. These forward-looking statements are
subject to a number of risks and uncertainties that could cause
actual results or events to differ materially from current
expectations. For instance, the distribution relationship with PACC
Pets may not have the expected outcomes, may not be successful or
may not expand as anticipated. Except as required by law, Avivagen
assumes no obligation to update the forward-looking statements, or
to update the reasons why actual results could differ from those
reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
For more information:Avivagen
Inc.Drew BasekDirector of Investor Relations100 Sussex Drive,
Ottawa, Ontario, Canada K1A 0R6 Phone: 416-540-0733E-mail:
d.basek@avivagen.com
Kym AnthonyChairman & Interim CEO100 Sussex Drive, Ottawa,
Ontario, Canada K1A 0R6 Head Office Phone: 613-949-8164Website:
www.avivagen.com
Copyright © 2018 Avivagen Inc. OxC-beta™ is a trademark of
Avivagen Inc.
Avivagen (TSXV:VIV)
Historical Stock Chart
From Apr 2024 to May 2024
Avivagen (TSXV:VIV)
Historical Stock Chart
From May 2023 to May 2024